About CIS Pharma’s cefuroxime application system
The cefuroxime application system is CIS Pharma’s patented drug/device combination for preparation and injection of cefuroxime intracameral antibiotic to prevent Endophthalmitis after cataract surgery. It meets the cataract surgeon’s need to dilute and inject 1mg cefuroxime in a safe, precise and standardized manner. Every year, 20 million cataract patients receive an intraocular lens. Endophthalmitis, also called intravitreal infection, is a rare but severe inflammatory condition of the eye, caused by microbial contamination during the surgical procedure. Cefuroxime intracameral prophylaxis was found to reduce the risk of Endophthalmitis by a factor 5, whereas topical antibiotics have no effect on the outcome.